Sarepta Therapeutics, INC Form 4 insider transactions

Dallan Murray, Chief Customer Officer of Sarepta Therapeutics, sold shares to cover tax obligations related to vesting restricted stock units.

Ian Michael Estepan, CFO of Sarepta Therapeutics, reports the sale of 1,370 shares of common stock to cover tax withholding obligations related to vesting of restricted stock units.

Louise Rodino-Klapac, Head of R&D and CSO at Sarepta Therapeutics, reports disposition of shares to cover tax obligations related to vesting of restricted stock units.

Chief Customer Officer Dallan Murray of Sarepta Therapeutics reports selling shares to cover tax obligations related to vesting restricted stock units.

Bilal Arif, Chief Tech Ops Officer at Sarepta Therapeutics, reports a transaction involving the disposal of shares to cover tax obligations and an acquisition through the Employee Stock Purchase Plan.

Chief Financial Officer of Sarepta Therapeutics, Ian Michael Estepan, reports the sale of 557 shares of common stock to cover tax withholding obligations related to vesting of restricted stock units.

Louise Rodino-Klapac, Head of R&D and CSO at Sarepta Therapeutics, reports disposition of shares to cover tax obligations and acquisition of shares through the Employee Stock Purchase Plan.

Cristin Rothfuss, EVP and General Counsel of Sarepta Therapeutics, reports the sale of shares to cover tax obligations related to vesting restricted stock units.

Chief Financial Officer of Sarepta Therapeutics, Ian Michael Estepan, reports acquiring 3,500 shares of common stock through performance-based restricted stock units.

Louise Rodino-Klapac, Head of R&D and CSO at Sarepta Therapeutics, reports the acquisition of 3,500 performance-based stock units that will vest in March 2025.

Chief Customer Officer Dallan Murray reports acquisition of 3,500 shares of Sarepta Therapeutics common stock through performance-based stock units.

Bilal Arif, Chief Tech Ops Officer at Sarepta Therapeutics, reports acquiring 3,500 shares of common stock through performance-based stock units.

Sarepta Therapeutics' Chief Financial Officer, Ian Michael Estepan, exercised stock options and sold a portion of the acquired shares to cover tax obligations on January 29, 2025.

Sarepta Therapeutics' Chief Financial Officer, Ian Michael Estepan, reported a charitable donation of 250 common shares on December 27, 2024.

Director Hans Wigzell of Sarepta Therapeutics exercised stock options and sold shares on December 12, 2024.

Kathryn Jean Boor, a director at Sarepta Therapeutics, sold 1,636 shares of common stock to cover taxes related to vesting restricted stock units.

Sarepta Therapeutics' EVP, General Counsel, Cristin Rothfuss, received 2,000 restricted stock units and options to purchase 4,000 shares of common stock.

Sarepta Therapeutics' Head of R&D, Louise Rodino-Klapac, sold 4,558 shares to cover tax obligations and now holds 67,630 shares.

Director Deirdre P. Connelly reports the acquisition of restricted stock units and stock options in Sarepta Therapeutics.

Director M. Kathleen Behrens reports a charitable gift of 746 shares of Sarepta Therapeutics common stock.

Ian Michael Estepan, CFO of Sarepta Therapeutics, sold 5,985 shares of common stock on August 30, 2024, at a price of $137.36 per share to cover tax obligations related to vesting restricted stock units.

Director Michael Chambers reported purchasing Sarepta Therapeutics (SRPT) shares in multiple transactions on August 16, 2024, increasing his indirect holdings.

M. Kathleen Behrens, a director of Sarepta Therapeutics, exercised stock options and reported changes in beneficial ownership of the company's common stock.

EVP and General Counsel of Sarepta Therapeutics, Ryan Brown, reports acquisition and disposal of company stock and derivative securities, including transactions related to performance stock units and a 10b5-1 trading plan.

Louise Rodino-Klapac, Head of R&D and CSO at Sarepta Therapeutics, reports acquisition and disposal of company stock and performance stock units.

Chief Customer Officer Dallan Murray reports acquisition and disposal of Sarepta Therapeutics stock related to performance stock units.

Ian Estepan, CFO of Sarepta Therapeutics, reports acquisition and disposal of common stock and performance stock units.

Chief Tech Ops Officer Bilal Arif reports the vesting of performance stock units (PSUs) and subsequent stock sales to cover tax obligations and under a pre-arranged trading plan.

Dallan Murray, Chief Customer Officer of Sarepta Therapeutics, sold 3,635 shares of common stock at $140 per share on May 2, 2024, under a pre-arranged 10b5-1 trading plan.

Director Hans Wigzell exercised stock options and sold shares of Sarepta Therapeutics on March 8, 2024.